ArticleACS omega2026
Evaluation of Phytocannabinoids as Antitumor Agents against Ovarian Cancer Cells in Combination with Carboplatin.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer is the second leading cause of death from gynecologic malignancy worldwide. The integration of phytocannabinoids into oncological care has outpaced our mechanistic understanding of their interactions with frontline chemotherapeutics. In this study, we provide a detailed pharmacological evaluation of two phytocannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), as antineoplastic agents against three epithelial ovarian cancer (EOC) cell lines. Using established EOC cell models, we demonstrate that both cannabinoids exhibit intrinsic antiproliferative activity, but CBD monotherapy significantly outperforms CBD-THC combinations. Furthermore, RT-qPCR and in silico analyses revealed a low density of classical receptors, indicating that cannabinoid efficacy in EOC may be primarily driven by receptor-independent mechanisms. Most importantly, we report that the coadministration of cannabinoids with carboplatin, the standard of care for EOC, paradoxically inhibits the platinum agent's antineoplastic efficacy. Our results challenge the "entourage effect" in an oncological context and provide a necessary cautionary framework for the use of cannabinoids alongside specific platinum-based regimens. Given the increasing use of cannabis among cancer patients, further robust studies examining interactions between cannabis and conventional chemotherapeutic agents are required to better evaluate safety and therapeutic efficacy in EOC treatment.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.